Preeclampsia: Pathogenesis, Diagnosis and Treatment
A special issue of Reproductive Medicine (ISSN 2673-3897).
Deadline for manuscript submissions: closed (31 July 2020) | Viewed by 19451
Special Issue Editor
2. Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia
Interests: pregnancy complications; screening for Down syndrome; autism spectrum disorders; tumor markers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Preeclampsia (PE) is a severe pregnancy complication that affects 2–8% of all pregnancies worldwide and accounts for the death of approximately 76,000 women and 500,000 foetuses per year. PE is characterized by new onset hypertension and proteinuria in the second half of pregnancy. The only known cure for PE is the termination of pregnancy, which increases the rate of preterm birth. Pathogenesis of this pregnancy complication has been investigated in many studies. Based on extensive PE research in the past few decades, the old two-stage model has been refined and lately even been extended to six stages.
I cordially invite authors and investigators within this complex field of universal interest to submit original research or review articles pertaining to this Special Issue, including studies and opinions on risk factors related to the development of the disease and molecular aspects of its pathogenesis.
I would appreciate it if the authors provided a brief section in their manuscript indicating the novelty of their findings or, in the case of review articles, provided personal views on a particular topic.
Prof. Dr. Joško Osredkar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reproductive Medicine is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pregnancy
- proteinuria
- hypertension
- preterm birth
- angiogenesis
- placental dysfunction
- PlGF, sFlt-1
- PAPP-A
- doppler
- treatment of hypertension
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.